Negative statin-related news stories decrease statin persistence and increase myocardial infarction and cardiovascular mortality: A nationwide prospective cohort study

European Heart Journal

Volumn 37, Issue 11, 2016, Pages 908-916

  Nielsen, Sune Fallgaard ^a   Nordestgaard, Børge Grønne ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Death from cardiovascular disease; Myocardial infarction; Statin compliance; Statin related news stories

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; ARTICLE; CARDIOVASCULAR MORTALITY; DENMARK; DIABETES MELLITUS; DRUG WITHDRAWAL; EDUCATIONAL STATUS; ETHNICITY; FEMALE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PUBLICATION; RESIDENTIAL AREA; SEX; AGED; FOLLOW UP; INFORMATION DISSEMINATION; MASS MEDIUM; MEDICATION COMPLIANCE; MIDDLE AGED; MYOCARDIAL INFARCTION; STATISTICS AND NUMERICAL DATA;

ADULT; AGED; COMMUNICATIONS MEDIA; DENMARK; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFORMATION DISSEMINATION; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROSPECTIVE STUDIES;

EID: 84983786894     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehv641     Document Type: Article

References (38)

1. Aronow WS. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomized placebo-controlled trial. J Am Geriatr Soc 2003;51:717-718.
2. Kashani A, Phillips CO, Foody JM, Wong Y, Mangalmurti S, Ko DT, Krumholz HM. Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation 2006;113:E809.
3. Ridker PM, Danielson E, Fonseca FAH, Genest J, Gotto AM, Kastelein JJP, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-2207.
4. Guyton JR, Bays HE, Grundy SM, Jacobson TA. An assessment by the statin intolerance panel: 2014 update. J Clin Lipidol 2014;8:S72-S81.
5. Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol 2006;97:52C-60C.
6. Mancini GBJ, Tashakkor AY, Baker S, Bergeron J, Fitchett D, Frohlich J, Genest J, Gupta M, Hegele RA, Ng DS, Pearson GJ, Pope J. Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian working group consensus update. Can J Cardiol 2013;29:1553-1568.
7. Richardson K, Schoen M, French B, Umscheid CA, Mitchell MD, Arnold SE, Heidenreich PA, Rader DJ, de Goma EM. Statins and cognitive function. Ann Intern Med 2013;159:688-697.
8. Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet 2012;380:565-571.
9. Stroes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK, Roden M, Stein E, Tokgozoglu L, Nordestgaard BG, Bruckert E, De BG, Krauss RM, Laufs U, Santos RD, Hegele RA, Hovingh GK, Leiter LA, Mach F, Marz W, Newman CB, Wiklund O, Jacobson TA, Catapano AL, Chapman MJ, Ginsberg HN. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J 2015;36:1012-1022.
10. Cohen JD, Brinton EA, Ito MK, Jacobson TA. Understanding statin use in America and gaps in patient education (USAGE): an internet-based survey of 10 138 current and former statin users. J Clin Lipidol 2012;6:208-215.
11. Jacobson TA. Toward 'Pain-Free' statin prescribing: clinical algorithm for diagnosis and management of myalgia. Mayo Clin Proc 2008;83:687-700.
12. Chodick G, Shalev V, Gerber Y, Heymann AD, Silber H, Simah V, Kokia E. Longterm persistence with statin treatment in a not-for-profit health maintenance organization: a population-based retrospective cohort study in Israel. Clin Ther 2008;30:2167-2179.
13. Chowdhury R, Khan H, Heydon E, Shroufi A, Fahimi S, Moore C, Stricker B, Mendis S, Hofman A, Mant J, Franco OH. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J 2013;34:2940-2948.
14. De Vera MA, Bhole V, Burns LC, Lacaille D. Impact of statin adherence on cardiovascular disease and mortality outcomes: a systematic review. BMJ 2014;78:684-698.
15. Ganga HV, Slim HB, Thompson PD. A systematic review of statin-induced muscle problems in clinical trials. Am Heart J 2014;168:6-15.
16. Ghatak A, Faheem O, Thompson PD. The genetics of statin-induced myopathy. Atherosclerosis 2010;210:337-343.
17. Maningat P, Breslow JL. Needed: pragmatic clinical trials for statin-intolerant patients. N Engl J Med 2011;365:2250-2251.
18. Rosenson RS, Baker SK, Jacobson TA, Kopecky SL, Parker BA. An assessment by the Statin Muscle Safety Task Force: 2014 update. J Clin Lipidol 2014;8:S58-S71.
19. Zhang HB, Plutzky J, Skentzos S, Morrison F, Mar. P, Shubina M, Turchin A. Discontinuation of statins in routine care settings: a cohort study. Ann Intern Med 2013;158:526-534.
20. Pedersen CB, Gotzsche H, Moller JO, Mortensen PB. The Danish Civil Registration System. A cohort of eight million persons. Dan Med Bull 2006;53:441-449.
21. Andersen TF, Madsen M, Jorgensen J, Mellemkjoer L, Olsen JH. The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull 1999;46:263-268.
22. Geneva SWHO. International Classification of Diseases and Related Health Problems, 10th revision, 2004. http://www.who.int/classifications/icd/en/.
23. Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein (a) and increased risk of myocardial infarction. JAMA 2009;301:2331-2339.
24. Nielsen SF, Nordestgaard BG. Statin use before diabetes diagnosis and risk of microvascular disease: a nationwide nested matched study. Lancet Diabetes Endocrinol 2014;2:894-900.
25. Donders ART, Heiden MGV, Stijnen T, Moyad MA. Review: a gentle introduction to imputation of missing values. J Clin Epidemiol 2006;59:1087-1091.
26. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999;94:496-509.
27. Mackinnon DP, Dwyer JH. Estimating mediated effects in prevention studies. Eval Rev 1993;17:144-158.
28. Mackinnon DP, Lockwood CM, Williams J. Confidence limits for the indirect effect: distribution of the product and resampling methods. Multivariate Behav Res 2004;39:99-128.
29. Bosch X, Poch E, Grau JM. Current concepts: rhabdomyolysis and acute kidney injury. N Engl J Med 2009;361:62-72.
30. Bruckert E, Hayem G, Dejager S, Yau C, Begaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients-the PRIMO study. Cardiovasc Drug Ther 2005;19:403-414.
31. Buettner C, Rippberger MJ, Smith JK, Leveille SG, Davis RB, Mittleman MA. Statin use and musculoskeletal pain among adults with and without arthritis. Am J Med 2012;125:176-182.
32. Yan YL, Qiu B, Hu LJ, Jing XD, Liu YJ, Deng SB, Du JL, She Q. Efficacy and safety evaluation of intensive statin therapy in older patients with coronary heart disease: a systematic review and meta-analysis. Eur J Clin Pharmacol 2013;69:2001-2009.
33. Sandoval D, Chacon J, Munoz R, Henriquez O, Koch E, Romero T. Influence of psychosocial factors on adherence to antihypertensive drug therapy. Results from a cardiovascular health program cohort followed in the metropolitan region of Santiago, Chile. Rev Med Chile 2014;142:1245-1252.
34. Knauer MJ, Urquhart BL, Schwabedissen HEMZ, Schwarz UI, Lemke CJ, Leake BF, Kim RB, Tirona RG. Human skeletal muscle drug transporters determine local exposure and toxicity of statins. Circ Res 2010;106:297-306.
35. Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, Gut I, Lathrop M, Collins R. SLCO1B1 variants and statin-induced myopathy-a genomewide study. N Engl J Med 2008;359:789-799.
36. Oh J, Ban MR, Miskie BA, Pollex RL, Hegele RA. Genetic determinants of statin intolerance. Lipids Health Dis 2007;6:7.
37. Stringer HAJ, Sohi GK, Maguire JA, Cote HCF. Decreased skeletal muscle mitochondrial DNA in patients with statin-induced myopathy. J Neurol Sci 2013;325:142-147.
38. Dormuth CR, Patrick AR, Shrank WH, Wright JM, Glynn RJ, Sutherland J, Brookhart MA. Statin adherence and risk of accidents a cautionary tale. Circulation 2009;119:2051-2057.